Investors Careers Contact Us

Synergy Pharmaceuticals Inc.

  • About Us
    • Management Team
    • Board of Directors
  • Research and Development
    • Uroguanylin
    • Trulance®
    • Dolcanatide
    • Investigator Initiated Trials
  • Therapeutic Focus
    • CIC
    • IBS-C
    • OIC
    • UC
    • Grants
  • News
    • Press Releases
    • Events & Presentations
    • Social Media
  • Investors
    • Investor Relations
    • Overview
    • News
    • News
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Financials
    • Financial Results
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Governance
    • Committee Composition
    • Governance Documents
    • Investor FAQ
    • Investor FAQ
  • About Us
    • Management Team
    • Board of Directors
  • Research and Development
    • Uroguanylin
    • Trulance®
    • Dolcanatide
    • Investigator Initiated Trials
  • Therapeutic Focus
    • CIC
    • IBS-C
    • OIC
    • UC
    • Grants
  • News
    • Press Releases
    • Events & Presentations
    • Social Media
  • Investors
    • Investor Relations
    • Overview
    • News
    • News
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Financials
    • Financial Results
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Governance
    • Committee Composition
    • Governance Documents
    • Investor FAQ
    • Investor FAQ
Careers Contact Us

Press Releases

  • Home
  • Investors
  • News
  • Press Releases
Investors
  • Overview
  • News
    • Press Releases
    • Events & Presentations
  • Financial Information
  • SEC Filings
  • Stock Information
  • Corporate Governance
  • Investor FAQ
  • Email Alerts

Investor Contacts

Investor Relations

Ted McHugh and Nicole Briguet
T: 212-584-7610
SynergyIR@edelman.com

Transfer Agent

Philadelphia Stock Transfer, Inc.
Bob Winterle
T: (484) 416-3124
bwinterle@philadelphiastocktransfer.com

Auditor

BDO USA, LLP

  • All News
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008

Synergy Pharmaceuticals Raises $8.6 Million in Common Stock Financing

Published on: Nov 12, 2009

View Press Release

Synergy Pharmaceuticals Announces Appointment of Dr. Alan F. Joslyn to Board of Directors

Published on: Oct 8, 2009

View Press Release

Synergy Pharmaceuticals to Present at the 17th Annual BioPartnering Europe Conference in London, UK

Published on: Oct 5, 2009

View Press Release

Synergy Pharmaceuticals Raises $7.09 Million in Common Stock Financing

Published on: Jul 7, 2009

View Press Release

Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorders at Upcoming Conference

Published on: May 26, 2009

View Press Release

Callisto Pharmaceuticals Redirects Atiprimod Clinical Development to Treat Rheumatoid Arthritis

Published on: Jan 27, 2009

View Press Release
RSS

Investor Contacts

Investor Relations

Ted McHugh and Nicole Briguet
T: 212-584-7610
SynergyIR@edelman.com

Transfer Agent

Philadelphia Stock Transfer, Inc.
Bob Winterle
T: (484) 416-3124
bwinterle@philadelphiastocktransfer.com

Auditor

BDO USA, LLP

Privacy Policy Terms of Use Sitemap Contact Us
Synergy Pharmaceuticals Inc.
Nasdaq: SGYP
Copyright 2019© Synergy Pharmaceuticals Inc.
420 Lexington Avenue, Suite 2012, New York, NY 10170, USA